Lantheus, as a collaborator on the SPLASH study, is likely to be affected by the same news that impacted POINT Biopharma. The extent of the impact may be slightly less for Lantheus, depending on its level of involvement and the market's perception of its role in the study. The importance is significant as the study's outcome can influence the company's product pipeline and future earnings. The confidence level is slightly lower than for POINT Biopharma due to the potential for varying market perceptions of each company's stake in the study results.

The decline in POINT Biopharma's stock price suggests that the topline results from the SPLASH study may have underwhelmed investors or did not meet the market's expectations. As the study is pivotal for the company's prostate cancer treatment, these results are highly relevant and important to the company's valuation and future revenue potential. The confidence in this analysis is high due to the direct correlation between clinical trial outcomes and biopharmaceutical stock performance, although without specific details on the study results, there is some uncertainty.